Janssen to fund Genmab renaissance with daratumumab licensing deal

Janssen Biotech (J&J) has agreed a global licence and development deal for Genmab's daratumumab (HuMax(r)-CD38), a human CD38 monoclonal antibody, which is in clinical testing for multiple myeloma. Genmab will receive $55 million up front under the agreement, and J&J will invest DKK475 million (around $80 million) in Genmab, making it the Danish biotech company's largest shareholder.